Stabilization of fenofibrate in low molecular weight hydroxypropylcellulose matrices produced by hot-melt extrusion

Drug Development and Industrial Pharmacy

Volumn 39, Issue 2, 2013, Pages 290-298

  Deng, Weibin ^a   Majumdar, Soumyajit ^a,b   Singh, Abhilasha ^a   Shah, Sejal ^a   Mohammed, Noorullah Naqvi ^a   Jo, Seongbong ^a,b   Pinto, Elanor ^c   Tewari, Divya ^c   Durig, Thomas ^c   Repka, Michael A ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c ASHLAND INC   (United States)

Author keywords

Crystallinity; Dissolution; Extrusion; Fenofibrate; Hot melt; Hydroxypropylcellulose; Immediate release; Poorly water soluble drug; Solubility; Stability; Thermal analysis

Indexed keywords

AMINO METHACRYLATE; COPOLYMER; CRYSTALLIN; FENOFIBRATE; HYDROXYPROPYLCELLULOSE; POLYMER; POVIDONE; SUGAR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; GLASS TRANSITION TEMPERATURE; MOLECULAR WEIGHT; STORAGE TEMPERATURE;

CELLULOSE; DRUG COMPOUNDING; DRUG STABILITY; FENOFIBRATE; HOT TEMPERATURE; HYPOLIPIDEMIC AGENTS; MOLECULAR WEIGHT; POLYMERS; SOLUBILITY;

EID: 84872474559     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.679280     Document Type: Article

References (45)

1. Merisko-Liversidge E (2002) Nanocrystals: resolving pharmaceutical formulation issues associated with poorly water-soluble compounds. In: Marty JJ, (Ed.) Particles. Orlando: Marcel Dekker
2. Crowley MM, Zhang F, Repka MA, Thumma S, Upadhye SB, Battu SK et al. (2007). Pharmaceutical applications of hot-melt extrusion: part I. Drug Dev Ind Pharm, 33:909-926. (Pubitemid 47463803)
3. Fukuda M, Miller DA, Peppas NA, McGinity JW. (2008). Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion. Int J Pharm, 350:188-196.
4. Hülsmann S, Backensfeld T, Keitel S, Bodmeier R. (2000). Melt extrusion-an alternative method for enhancing the dissolution rate of 17 beta-estradiol hemihydrate. Eur J Pharm Biopharm, 49:237-242. (Pubitemid 30229872)
5. Lakshman JP, Cao Y, Kowalski J, Serajuddin AT. (2008). Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug. Mol Pharm, 5:994-1002.
6. Miller DA, McConville JT, Yang W, Williams RO 3rd, McGinity JW. (2007). Hot-melt extrusion for enhanced delivery of drug particles. J Pharm Sci, 96:361-376. (Pubitemid 46363567)
7. Nakamichi K, Nakano T, Yasuura H, Izumi S, Kawashima Y. (2002). The role of the kneading paddle and the effects of screw revolution speed and water content on the preparation of solid dispersions using a twin-screw extruder. Int J Pharm, 241:203-211. (Pubitemid 34718022)
8. Perissutti B, Newton JM, Podczeck F, Rubessa F. (2002). Preparation of extruded carbamazepine and PEG 4000 as a potential rapid release dosage form. Eur J Pharm Biopharm, 53:125-132. (Pubitemid 34037004)
9. Prodduturi S, Urman KL, Otaigbe JU, Repka MA. (2007). Stabilization of hot-melt extrusion formulations containing solid solutions using polymer blends. AAPS PharmSciTech, 8:Article 50.
10. Repka MA, Battu SK, Upadhye SB, Thumma S, Crowley MM, Zhang F et al. (2007). Pharmaceutical applications of hot-melt extrusion: part II. Drug Dev Ind Pharm, 33:1043-1057. (Pubitemid 350034836)
11. Repka MA, Majumdar S, Kumar Battu S, Srirangam R, Upadhye SB. (2008). Applications of hot-melt extrusion for drug delivery. Expert Opin Drug Deliv, 5:1357-1376.
12. Six K, Berghmans H, Leuner C, Dressman J, Van Werde K, Mullens J et al. (2003). Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion, Part II. Pharm Res, 20:1047-1054. (Pubitemid 36774276)
13. Sun Y, Rui Y, Wenliang Z, Tang X. (2008). Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. Int J Pharm, 359:144-149.
14. Verreck G, Six K, Van den Mooter G, Baert L, Peeters J, Brewster ME. (2003). Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion-Part I. Int J Pharm, 251:165-174. (Pubitemid 36071471)
15. Ranzani LS, Font J, Galimany F, Santanach A, Gomez-Gomar AM, Casadevall G et al. (2011). Enhanced in vivo absorption of CB-1 antagonist in rats via solid solutions prepared by hot-melt extrusion. Drug Dev Ind Pharm, 37:694-701.
16. Mcginity JW, Repka MA, Koleng JJ, Zhang F. (2006) Hot-melt extrusion technology. IN Swarbrick J. (Ed.) Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker, Inc.
17. Lulla A, Malhotra G. (2009) Solid pharmaceutical dosage form. In: Organization, WIP. (ed.) A61K 9/14(2006.01), A61K 31/167(2006.01), A61K 9/20(2006.01) ed.
18. Buch P, Holm P, Thomassen JQ, Scherer D, Branscheid R, Kolb U et al. (2010). IVIVC for fenofibrate immediate release tablets using solubility and permeability as in vitro predictors for pharmacokinetics. J Pharm Sci, 99:4427-4436.
19. Vogt M, Kunath K, Dressman JB. (2008). Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations. Eur J Pharm Biopharm, 68:283-288.
20. de Waard H, Hinrichs WL, Frijlink HW. (2008). A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying. J Control Release, 128:179-183.
21. GóRniak A, Wojakowska A, Karolewicz BZ, Pluta J. (2011) Phase diagram and dissolution studies of the fenofibrate-acetylsalicylic acid system. J Therm Anal Calorim, 104:1195-1200.
22. Sanganwar GP, Gupta RB. (2008). Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide. Int J Pharm, 360:213-218.
23. Zhou D, Zhang GG, Law D, Grant DJ, Schmitt EA. (2002). Physical stability of amorphous pharmaceuticals: importance of configurational thermodynamic quantities and molecular mobility. J Pharm Sci, 91:1863-1872. (Pubitemid 34810531)
24. Khougaz K, Clas SD. (2000). Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers. J Pharm Sci, 89:1325-1334.
25. Kim JH, Choi HK. (2002). Effect of additives on the crystallization and the permeation of ketoprofen from adhesive matrix. Int J Pharm, 236:81-85.
26. Konno H, Taylor LS. (2006). Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci, 95:2692-2705. (Pubitemid 46093176)
27. Kotiyan PN, Vavia PR. (2001). Eudragits: role as crystallization inhibitors in drug-in-adhesive transdermal systems of estradiol. Eur J Pharm Biopharm, 52:173-180. (Pubitemid 32755896)
28. Ma X, Taw J, Chiang CM. (1996) Control of drug crystallization in transdermal matrix system, Int J Pharm 142:115-119. (Pubitemid 26343836)
29. Urbanetz NA. (2006). Stabilization of solid dispersions of nimodipine and polyethylene glycol 2000. Eur J Pharm Sci, 28:67-76.
30. Yang J, Grey K, Doney J. (2010). An improved kinetics approach to describe the physical stability of amorphous solid dispersions. Int J Pharm, 384:24-31.
31. Brady JE, Durig T, Shang SS. (2009). Polymer properties and characterization. In: Qiu Y, Chen Y., Zhang GGZ, Liu L & Porter WR. (Eds.) Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice. 1 ed., New York: Academic Press.
32. Gustow EE, Ryde TA, Ruddy SB, Jain R, Patel R, Wilkins M, John, & Ryde NP. (2009) Fenofibrate dosage forms. In: Organization, WIP. (Ed.) A61K 9/14(2006.01), A61K 31/216(2006.01) ed.
33. Jamzad S, Fassihi R. (2006). Role of surfactant and pH on dissolution properties of fenofibrate and glipizide-a technical note. AAPS PharmSciTech, 7:E33.
34. Li X, Gu L, Xu Y, Wang Y. (2009). Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats. Drug Dev Ind Pharm, 35:827-833.
35. Srinarong P, Faber JH, Visser MR, Hinrichs WL, Frijlink HW. (2009). Strongly enhanced dissolution rate of fenofibrate solid dispersion tablets by incorporation of superdisintegrants. Eur J Pharm Biopharm, 73:154-161.
36. Shah VP, Tsong Y, Sathe P, Liu JP. (1998). In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f2. Pharm Res, 15:889-896. (Pubitemid 28307831)
37. Kanaujia P, Lau G, Ng WK, Widjaja E, Schreyer M, Hanefeld A et al. (2011). Investigating the effect of moisture protection on solidstate stability and dissolution of fenofibrate and ketoconazole solid dispersions using PXRD, HSDSC and Raman microscopy. Drug Dev Ind Pharm, 37:1026-1035.
38. Kaizawa A, Maruoka N, Kawai A, Kamano H, Jozuka T, Senda T, Akiyama T. (2007) Thermophysical and heat transfer properties of phase change material candidate for waste heat transportation system. Heat and Mass Transfer, 44:763-769.
39. He H, Yang R, Tang X. (2010). In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion. Drug Dev Ind Pharm, 36:681-687.
40. Mididoddi PK, Repka MA. (2007). Characterization of hot-melt extruded drug delivery systems for onychomycosis. Eur J Pharm Biopharm, 66:95-105. (Pubitemid 46412960)
41. Greenhalgh DJ, Williams AC, Timmins P, York P. (1999). Solubility parameters as predictors of miscibility in solid dispersions. J Pharm Sci, 88:1182-1190. (Pubitemid 29526305)
42. Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JA. (2008). Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol Pharm, 5:1003-1019.
43. Alonzo DE, Zhang GG, Zhou D, Gao Y, Taylor LS. (2010). Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res, 27:608-618.
44. Battu SK, Repka MA, Majumdar S, Madhusudan RY. (2007). Formulation and evaluation of rapidly disintegrating fenoverine tablets: effect of superdisintegrants. Drug Dev Ind Pharm, 33:1225-1232. (Pubitemid 350208742)
45. Tho I, Liepold B, Rosenberg J, Maegerlein M, Brandl M, Fricker G. (2010). Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media. Eur J Pharm Sci, 40:25-32.